About the Company

Bellus Health (TSX: BLU.TO) is a clinical stage biotechnology company focused on developing therapies for rare diseases. Lead program KIACTA is being evaluated in a confirmatory Phase III trial for patients with AA amyloidosis, which affects an estimated 10,000 to 15,000 individuals in the US and Europe each year. KIACTA is partnered with Auven Therapeutics (Private), who is funding the Phase III study. Two additional programs are expected to enter Phase II in the near-term, including KIACTA for sarcoidosis and an antibody program, Shigamab, for Shiga toxin induced Hemolytic Uremic Syndrome (STEC-HUS).

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research